Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.

Wang L, Yang H, Zamperone A, Diolaiti D, Palmbos PL, Abel EV, Purohit V, Dolgalev I, Rhim AD, Ljungman M, Hadju CH, Halbrook CJ, Bar-Sagi D, di Magliano MP, Crawford HC, Simeone DM.

Genes Dev. 2019 Jun 1;33(11-12):641-655. doi: 10.1101/gad.323303.118. Epub 2019 May 2.

PMID:
31048544
2.

BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis.

Das S, Bar-Sagi D.

Oncogene. 2019 Apr;38(17):3316-3324. doi: 10.1038/s41388-018-0668-3. Epub 2019 Jan 11.

3.

The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.

Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.

Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.

PMID:
30554948
4.

EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration.

Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, Bar-Sagi D, Stanger BZ.

Dev Cell. 2018 Jun 18;45(6):681-695.e4. doi: 10.1016/j.devcel.2018.05.027.

5.

Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-β exposure.

Handler J, Cullis J, Avanzi A, Vucic EA, Bar-Sagi D.

Oncogene. 2018 Aug;37(31):4334-4342. doi: 10.1038/s41388-018-0264-6. Epub 2018 May 1.

6.

Kras and Tumor Immunity: Friend or Foe?

Cullis J, Das S, Bar-Sagi D.

Cold Spring Harb Perspect Med. 2018 Sep 4;8(9). pii: a031849. doi: 10.1101/cshperspect.a031849. Review.

PMID:
29229670
7.

Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer.

Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D.

Cell Rep. 2017 Jul 18;20(3):558-571. doi: 10.1016/j.celrep.2017.06.062.

8.

The G protein-coupled receptor GPR31 promotes membrane association of KRAS.

Fehrenbacher N, Tojal da Silva I, Ramirez C, Zhou Y, Cho KJ, Kuchay S, Shi J, Thomas S, Pagano M, Hancock JF, Bar-Sagi D, Philips MR.

J Cell Biol. 2017 Aug 7;216(8):2329-2338. doi: 10.1083/jcb.201609096. Epub 2017 Jun 15.

9.

Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.

Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D.

Cancer Immunol Res. 2017 Mar;5(3):182-190. doi: 10.1158/2326-6066.CIR-16-0125. Epub 2017 Jan 20.

10.

Simulating Heterogeneous Tumor Cell Populations.

Sundstrom A, Bar-Sagi D, Mishra B.

PLoS One. 2016 Dec 28;11(12):e0168984. doi: 10.1371/journal.pone.0168984. eCollection 2016.

11.

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors.

Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Mayers JR, Wyckoff J, Del Rosario AM, Whitman M, Chin CR, Condon KJ, Lammers A, Kellersberger KA, Stall BK, Stephanopoulos G, Bar-Sagi D, Han J, Rabinowitz JD, Cima MJ, Langer R, Vander Heiden MG.

Nat Med. 2017 Feb;23(2):235-241. doi: 10.1038/nm.4256. Epub 2016 Dec 26.

12.

Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules.

Grabocka E, Bar-Sagi D.

Cell. 2016 Dec 15;167(7):1803-1813.e12. doi: 10.1016/j.cell.2016.11.035.

13.

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.

Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VRK, Avanzi A, Tippens D, Narayanan R, Jang JE, Newman E, Pillarisetty VG, Dustin ML, Bar-Sagi D, Hajdu C, Miller G.

Cell. 2016 Sep 8;166(6):1485-1499.e15. doi: 10.1016/j.cell.2016.07.046. Epub 2016 Aug 25.

14.

One-way membrane trafficking of SOS in receptor-triggered Ras activation.

Christensen SM, Tu HL, Jun JE, Alvarez S, Triplet MG, Iwig JS, Yadav KK, Bar-Sagi D, Roose JP, Groves JT.

Nat Struct Mol Biol. 2016 Sep;23(9):838-46. doi: 10.1038/nsmb.3275. Epub 2016 Aug 8.

15.

Histological Image Processing Features Induce a Quantitative Characterization of Chronic Tumor Hypoxia.

Sundstrom A, Grabocka E, Bar-Sagi D, Mishra B.

PLoS One. 2016 Apr 19;11(4):e0153623. doi: 10.1371/journal.pone.0153623. eCollection 2016.

16.

IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia.

Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, Bar-Sagi D.

Cancer Discov. 2016 Mar;6(3):247-55. doi: 10.1158/2159-8290.CD-15-0843. Epub 2015 Dec 29.

17.

High-content, full genome siRNA screen for regulators of oncogenic HRAS-driven macropinocytosis.

Fennell M, Commisso C, Ramirez C, Garippa R, Bar-Sagi D.

Assay Drug Dev Technol. 2015 Sep;13(7):347-55. doi: 10.1089/adt.2015.660. Epub 2015 Aug 12.

18.

Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.

Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD.

Cancer Res. 2015 Feb 1;75(3):544-53. doi: 10.1158/0008-5472.CAN-14-2211.

19.

Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.

Grabocka E, Commisso C, Bar-Sagi D.

Clin Cancer Res. 2015 Mar 15;21(6):1243-7. doi: 10.1158/1078-0432.CCR-14-0650. Epub 2014 Nov 25. Review.

20.

E-cadherin-mediated cell coupling is required for apoptotic cell extrusion.

Lubkov V, Bar-Sagi D.

Curr Biol. 2014 Apr 14;24(8):868-74. doi: 10.1016/j.cub.2014.02.057. Epub 2014 Apr 3.

21.

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D.

Cancer Cell. 2014 Feb 10;25(2):243-56. doi: 10.1016/j.ccr.2014.01.005.

22.

Determining the macropinocytic index of cells through a quantitative image-based assay.

Commisso C, Flinn RJ, Bar-Sagi D.

Nat Protoc. 2014 Jan;9(1):182-92. doi: 10.1038/nprot.2014.004. Epub 2014 Jan 2.

23.

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Court H, Amoyel M, Hackman M, Lee KE, Xu R, Miller G, Bar-Sagi D, Bach EA, Bergö MO, Philips MR.

J Clin Invest. 2013 Nov;123(11):4681-94.

24.

Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.

Dultz LA, Dhar S, Ogilvie JB, Heller KS, Bar-Sagi D, Patel KN.

Surgery. 2013 Dec;154(6):1239-44; discussion 1244-5. doi: 10.1016/j.surg.2013.06.024. Epub 2013 Oct 2.

25.

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.

Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D.

Nature. 2013 May 30;497(7451):633-7. doi: 10.1038/nature12138. Epub 2013 May 12.

26.

Microdissection and culture of murine pancreatic ductal epithelial cells.

Pylayeva-Gupta Y, Lee KE, Bar-Sagi D.

Methods Mol Biol. 2013;980:267-79. doi: 10.1007/978-1-62703-287-2_14.

PMID:
23359159
27.

An orthosteric inhibitor of the RAS-SOS interaction.

Nickerson S, Joy ST, Arora PS, Bar-Sagi D.

Enzymes. 2013;34 Pt. B:25-39. doi: 10.1016/B978-0-12-420146-0.00002-0. Epub 2013 Nov 7. Review.

PMID:
25034099
28.

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis.

Jeng HH, Taylor LJ, Bar-Sagi D.

Nat Commun. 2012;3:1168. doi: 10.1038/ncomms2173.

29.

MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.

Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, Badar S, Hajdu CH, Frey AB, Bar-Sagi D, Miller G.

J Exp Med. 2012 Aug 27;209(9):1671-87. doi: 10.1084/jem.20111706. Epub 2012 Aug 20.

30.

Escorting Ras.

Zheng ZY, Xu L, Bar-Sagi D, Chang EC.

Small GTPases. 2012 Oct-Dec;3(4):236-9. doi: 10.4161/sgtp.20460. Epub 2012 Jun 27.

31.

Regulation of RAS oncogenicity by acetylation.

Yang MH, Nickerson S, Kim ET, Liot C, Laurent G, Spang R, Philips MR, Shan Y, Shaw DE, Bar-Sagi D, Haigis MC, Haigis KM.

Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10843-8. doi: 10.1073/pnas.1201487109. Epub 2012 Jun 18.

32.

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D.

Cancer Cell. 2012 Jun 12;21(6):836-47. doi: 10.1016/j.ccr.2012.04.024.

33.

VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression.

Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D, Mukhopadhyay D.

Cancer Res. 2012 Aug 15;72(16):3912-8. doi: 10.1158/0008-5472.CAN-11-4058. Epub 2012 Jun 12.

34.

EZH2 couples pancreatic regeneration to neoplastic progression.

Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, Pylayeva-Gupta Y, Miller G, Margueron R, Reinberg D, Bar-Sagi D.

Genes Dev. 2012 Mar 1;26(5):439-44. doi: 10.1101/gad.181800.111.

35.

CHMP6 and VPS4A mediate the recycling of Ras to the plasma membrane to promote growth factor signaling.

Zheng ZY, Cheng CM, Fu XR, Chen LY, Xu L, Terrillon S, Wong ST, Bar-Sagi D, Songyang Z, Chang EC.

Oncogene. 2012 Oct 25;31(43):4630-8. doi: 10.1038/onc.2011.607. Epub 2012 Jan 9.

36.

Regulating the regulator: post-translational modification of RAS.

Ahearn IM, Haigis K, Bar-Sagi D, Philips MR.

Nat Rev Mol Cell Biol. 2011 Dec 22;13(1):39-51. doi: 10.1038/nrm3255. Review.

37.

RAS oncogenes: weaving a tumorigenic web.

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D.

Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106. Review.

38.

An orthosteric inhibitor of the Ras-Sos interaction.

Patgiri A, Yadav KK, Arora PS, Bar-Sagi D.

Nat Chem Biol. 2011 Jul 17;7(9):585-7. doi: 10.1038/nchembio.612.

39.

Perturbation of cytoskeleton dynamics by the opposing effects of Rac1 and Rac1b.

Nimnual AS, Taylor LJ, Nyako M, Jeng HH, Bar-Sagi D.

Small GTPases. 2010 Sep;1(2):89-97.

40.

Spry2 expression correlates with BRAF mutation in thyroid cancer.

Xu L, Zhou JL, Cohen M, Bar-Sagi D, Patel KN.

Surgery. 2010 Dec;148(6):1282-7; discussion 1287. doi: 10.1016/j.surg.2010.09.028.

PMID:
21134562
41.

Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.

Lee KE, Bar-Sagi D.

Cancer Cell. 2010 Nov 16;18(5):448-58. doi: 10.1016/j.ccr.2010.10.020.

42.

Fibronectin growth factor-binding domains are required for fibroblast survival.

Lin F, Ren XD, Pan Z, Macri L, Zong WX, Tonnesen MG, Rafailovich M, Bar-Sagi D, Clark RA.

J Invest Dermatol. 2011 Jan;131(1):84-98. doi: 10.1038/jid.2010.253. Epub 2010 Sep 2.

43.

Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination.

Xu L, Lubkov V, Taylor LJ, Bar-Sagi D.

Curr Biol. 2010 Aug 10;20(15):1372-7. doi: 10.1016/j.cub.2010.06.051. Epub 2010 Jul 22.

44.

Signaling endosomes: seeing is believing.

Miaczynska M, Bar-Sagi D.

Curr Opin Cell Biol. 2010 Aug;22(4):535-40. doi: 10.1016/j.ceb.2010.05.007. Epub 2010 Jun 9. Review.

45.

Allosteric gating of Son of sevenless activity by the histone domain.

Yadav KK, Bar-Sagi D.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3436-40. doi: 10.1073/pnas.0914315107. Epub 2010 Feb 4.

46.

Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless.

Gureasko J, Kuchment O, Makino DL, Sondermann H, Bar-Sagi D, Kuriyan J.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3430-5. doi: 10.1073/pnas.0913915107. Epub 2010 Feb 4.

47.

Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.

Connolly MK, Mallen-St Clair J, Bedrosian AS, Malhotra A, Vera V, Ibrahim J, Henning J, Pachter HL, Bar-Sagi D, Frey AB, Miller G.

J Leukoc Biol. 2010 Apr;87(4):713-25. doi: 10.1189/jlb.0909607. Epub 2009 Dec 30.

48.

Characterization of a Ras mutant with identical GDP- and GTP-bound structures .

Ford B, Boykevisch S, Zhao C, Kunzelmann S, Bar-Sagi D, Herrmann C, Nassar N.

Biochemistry. 2009 Dec 8;48(48):11449-57. doi: 10.1021/bi901479b.

49.

In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha.

Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A, Pachter HL, Bar-Sagi D, Frey AB, Miller G.

J Clin Invest. 2009 Nov;119(11):3213-25. doi: 10.1172/JCI37581. Epub 2009 Oct 12.

50.

Raf-1 and squamous cell carcinoma: Rok-ing the boat.

Grabocka E, Bar-Sagi D.

Cancer Cell. 2009 Aug 4;16(2):85-6. doi: 10.1016/j.ccr.2009.07.012.

Supplemental Content

Loading ...
Support Center